Program
trospium chloride
Also written as “Xanomeline/trospium chloride”, “Xanomeline/Trospium Chloride Capsule” and “Xanomeline/Trospium Chloride”.
Its studies are mostly in Schizophrenia · Urinary Bladder, Overactive · Alzheimer Disease · Mania · Pulmonary Disease, Chronic Obstructive, led by 3 companies.
Drug pageTrospium chloride: every studyAll 18 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 97 open or running | phase 4since Oct 13, 2025 | Jul 6, 2016 | Dec 3, 2026phase 1 · NCT07204418 |
| AbbVieits history only | 50 open or running | phase 4since Mar 16, 2009 | Mar 16, 2009 | none ahead |
| Keenova Therapeuticsits history only | 10 open or running | phase 2since Apr 24, 2007 | Apr 24, 2007 | none ahead |
Also a collaborator on its studies: Alkermes.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Bristol-Myers Squibb only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 6, 2016First study: phase 1 study in SchizophreniaFirst studyNCT02831231 · 70 enrolled · United States
- Jun 2, 20252 phase 3 studies in Alzheimer DiseaseNCT07011745, NCT07011732
- Jun 23, 2025Phase 1 study in Healthy VolunteersNCT07063342 · 236 planned · United Kingdom
- Aug 21, 2025Phase 3 study in ManiaNCT07140913 · 424 planned · United States, Argentina, Bulgaria and more
- Sep 24, 2025Phase 1 study in Healthy VolunteersNCT07204418 · 56 planned · United States
- Oct 13, 2025Phase 4 study in SchizophreniaNCT07221877 · 60 planned · United States
- Nov 21, 2025Phase 4 study in Healthy VolunteersNCT07257120 · 10 enrolled · United States
- Jun 30, 2026Phase 3 study in SchizophreniaNCT07686263 · 472 planned · United States, Argentina, Bulgaria and more
Ahead
- Dec 3, 2026Primary completion: phase 1 study in Healthy VolunteersNCT07204418
- Mar 29, 2027Primary completion: phase 1 study in Healthy VolunteersNCT07063342
- Jun 28, 2027Primary completion: phase 3 study in ManiaNCT07140913
- Dec 30, 2027Primary completion: phase 4 study in SchizophreniaNCT07221877
TargetBeta
“Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Glycopyrrolaterule | Novartis | phase 4 | 87 |
| trospiumrule | Bristol-Myers Squibb | phase 4 | 21 |
| Atropinerule | Laboratorios Sophia S.A de C.V. | phase 3 | 17 |
Studies
All 9 Bristol-Myers Squibb leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07686263Schizophrenia · United States, Argentina, Bulgaria and more | 3 | Recruiting | Mar 3, 2029 | 472 |
| NCT07257120Healthy Volunteers · United States | 4 | Completed | Jun 8, 2026 | 10 |
| NCT07221877Schizophrenia · United States | 4 | Recruiting | Dec 30, 2027 | 60 |
| NCT07204418Healthy Volunteers · United States | 1 | Recruiting | Dec 3, 2026 | 56 |
| NCT07140913Mania · United States, Argentina, Bulgaria and more | 3 | Recruiting | Jun 28, 2027 | 424 |
| NCT07063342Healthy Volunteers · United Kingdom | 1 | Recruiting | Mar 29, 2027 | 236 |
| NCT07011745Alzheimer Disease · United States, Argentina, Chile and more | 3 | Recruiting | Nov 3, 2028 | 426 |
| NCT07011732Alzheimer Disease · United States, Argentina, Brazil and more | 3 | Recruiting | Nov 24, 2028 | 426 |
| NCT02831231Schizophrenia · United States | 1 | Completed | Oct 28, 2016 | 70 |
How it is read
Names in the registry
- “Xanomeline/trospium chloride”, 2 entries
- “Xanomeline/Trospium Chloride Capsule”, 2 entries
- “Xanomeline/Trospium Chloride”, 2 entries
- “Trospium Chloride”, 2 entries
- “trospium chloride”, 2 entries
Conditions, from the studies’ own filings
- Schizophrenia, 3 studies
- Urinary Bladder, Overactive, 3 studies
- Alzheimer Disease, 2 studies
- Mania, 1 study
- Pulmonary Disease, Chronic Obstructive, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.